NCT03264404View on ClinicalTrials.gov

Azacitidine and Pembrolizumab in Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

October 1, 2021

Study Completion Date

December 3, 2024

Conditions
Pancreas Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV every 3 weeks until progression

DRUG

Azacitidine

50 mg/m2 subcutaneous daily for 5 days every 28 days

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Susan E. Bates

OTHER

NCT03264404 - Azacitidine and Pembrolizumab in Pancreatic Cancer | Biotech Hunter | Biotech Hunter